Cardiome/Astellas’ Vernakalant IV ACT 2 Study Positive For Post-Surgical Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
Study could bode well for oral formulation for maintenance of heart rhythm after atrial fibrillation.
You may also be interested in...
Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.
Astellas Pharma’s Vernakalant For Atrial Fibrillation Goes Before FDA Panel
FDA’s Cardiovascular and Renal Drugs Advisory Committee considers Astellas’ NDA re-submission for the indication Dec. 11.
FDA Advisory Committee Meeting Planned To Review Atrial Fibrillation Drugs
Safety and efficacy of Cardiome/Astellas’ vernakalant and Solvay’s tedisamil will be debated during the Dec. 11-12 meeting, according to Cardiome.